Misplaced Pages

McN 5707: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 01:49, 20 December 2024 editGraeme Bartlett (talk | contribs)Administrators250,058 edits more ids← Previous edit Latest revision as of 16:36, 25 December 2024 edit undoRodw (talk | contribs)Autopatrolled, Event coordinators, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers773,834 editsm Disambiguating links to McNeil (link changed to McNeil Consumer Healthcare) using DisamAssist. 
Line 61: Line 61:
| StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N | StdInChIKey = KWMNBUDYCCTHHL-SJLPKXTDSA-N
}} }}
Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref> Mcn 5707 is a ] agent designated for the treatment of depression. It was developed by ] of ] (now Johnson & Johnson) in the 1980s.<ref>{{cite journal | vauthors = Maryanoff BE, Shank RP, Gardocki JF | date = 1986 | title = McN-5707 and McN-5652-Z | journal = Drugs of the Future | volume = 11 | issue = 1 | pages = 18 | doi = 10.1358/dof.1986.011.01.51629 }}</ref><ref name="pmid6747993">{{cite journal | vauthors = Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR | title = Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin | journal = Journal of Medicinal Chemistry | volume = 27 | issue = 8 | pages = 943–6 | date = August 1984 | pmid = 6747993 | doi = 10.1021/jm00374a001 }}</ref>


For related agents, see ], ], ], ] & ]. For related agents, see ], ], ], ] & ].

Latest revision as of 16:36, 25 December 2024

Pharmaceutical compound
Mcn 5707
Clinical data
Other namesMcN-5707
Identifiers
IUPAC name
  • (6R,10bR)-6-(2-chlorophenyl)-1,2,3,5,6,10b-hexahydropyrroloisoquinoline
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H18ClN
Molar mass283.80 g·mol
3D model (JSmol)
SMILES
  • C1C2C3=CC=CC=C3(CN2C1)C4=CC=CC=C4Cl
InChI
  • InChI=1S/C18H18ClN/c19-17-9-4-3-7-14(17)16-12-20-11-5-10-18(20)15-8-2-1-6-13(15)16/h1-4,6-9,16,18H,5,10-12H2/t16-,18-/m1/s1
  • Key:KWMNBUDYCCTHHL-SJLPKXTDSA-N

Mcn 5707 is a SNDRI agent designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.

For related agents, see JNJ-7925476, McN 4612-z, McN-5292, McN-5558 & McN5652.

References

  1. Maryanoff BE, Shank RP, Gardocki JF (1986). "McN-5707 and McN-5652-Z". Drugs of the Future. 11 (1): 18. doi:10.1358/dof.1986.011.01.51629.
  2. Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, et al. (August 1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin". Journal of Medicinal Chemistry. 27 (8): 943–6. doi:10.1021/jm00374a001. PMID 6747993.
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Stimulants
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Pyrrolidines
Racetams
Tropanes
Tryptamines
Others
ATC code: N06B
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
Categories:
McN 5707: Difference between revisions Add topic